• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Frequency and predictors of diagnostic coronary angiography and percutaneous coronary intervention related to stroke
CONCLUSIONS: Based on the large national registry, PCI ± DCA is associated with fewer risk factors and lower rate of periprocedural strokes than isolated DCA.PMID:34472076 | DOI:10.33963/KP.a2021.0100
Source: Polish Heart Journal - September 2, 2021 Category: Cardiology Authors: Bart łomiej Staszczak Krzysztof P Malinowski Wojciech Wa ńha Zbigniew Siudak Magdalena J ędrychowska Micha ł Susuł S ławomir Surowiec Szymon Darocha Andrzej Surdacki Marcin Kurzyna Wojciech Wojakowski Jacek Legutko Krzysztof Bartu ś Stanis ław Bar Source Type: research

Comparison of Heparin and Bivalirudin in Patients Undergoing Orbital Atherectomy.
CONCLUSION: Both heparin and bivalirudin were safe and effective antithrombotic agents for patients who underwent orbital atherectomy. A randomized trial is needed to determine the antithrombotic agent of choice for orbital atherectomy. PMID: 29086730 [PubMed - in process]
Source: The Journal of Invasive Cardiology - November 2, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction HORIZONS-AMI Substudy)
The present study sought to determine the extent to which adverse angiographic events encountered during percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI) are associated with adverse clinical outcomes. Patients with STEMI represent a cohort at particularly high risk of intraprocedural thrombotic events (IPTEs). The overall frequency and implications of IPTEs occurring in patients with STEMI have not been systematically quantified in previous studies. A total of 3,163 patients undergoing primary percutaneous coronary intervention with stent implantation for STEMI in the Harmonizing Ou...
Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Ajay J. Kirtane, Prabhdeep Sandhu, Roxana Mehran, Margaret McEntegart, Ecaterina Cristea, Sorin J. Brener, Ke Xu, Martin Fahy, Philippe Généreux, Jeffrey D. Wessler, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research

Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials
BackgroundIn the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial, 3,602 patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) treated with bivalirudin had lower bleeding and mortality rates, but higher acute stent thrombosis rates compared with heparin + a glycoprotein IIb/IIIa inhibitor (GPI). Subsequent changes in primary PCI, including the use of potent P2Y12 inhibitors, frequent radial intervention, and pre-hospital medication administration, were incorporated into the EUROMAX (European Ambu...
Source: Journal of the American College of Cardiology - January 5, 2015 Category: Cardiology Source Type: research

Impact of Arterial Access Site on Outcomes After Primary Percutaneous Coronary Intervention: Prespecified Subgroup Analysis From the EUROMAX Trial Coronary Interventions
Conclusions— In this prespecified analysis from EUROMAX, radial access was preferred in lower risk patients and did not improve clinical outcomes. Bivalirudin was associated with less bleeding irrespective of access site. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01087723.
Source: Circulation: Cardiovascular Interventions - June 8, 2015 Category: Cardiology Authors: Hamon, M., Coste, P., van't Hof, A., Ten Berg, J., Clemmensen, P., Tabone, X., Benamer, H., Kristensen, S. D., Cavallini, C., Marzocchi, A., Hamm, C., Kanic, V., Bernstein, D., Anthopoulos, P., Deliargyris, E. N., Steg, P. G. Tags: Cardiovascular Pharmacology, Catheter-based coronary and valvular interventions: other, Acute myocardial infarction Coronary Interventions Source Type: research

Analysis shows increased risk of early stroke with new-onset atrial fibrillation post-TAVR
(Society for Cardiovascular Angiography and Interventions) Results from 'Effect of bivalirudin versus unfractionated heparin in patients with baseline or new-onset atrial fibrillation in transcatheter aortic valve replacement: From the BRAVO-3 randomized trial' were presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.
Source: EurekAlert! - Social and Behavioral Science - May 11, 2017 Category: International Medicine & Public Health Source Type: news

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Publication date: Available online 25 August 2018Source: The LancetAuthor(s): Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andó, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Nazzaro, Alessandro Lupi, Bernardo CorteseSummaryBackgroundThe Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of ra...
Source: The Lancet - August 25, 2018 Category: General Medicine Source Type: research

Periprocedural Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction.
CONCLUSION: The periprocedural use of bivalirudin vs UFH was associated with similar rates of MACE and bleeding. Given the expense of bivalirudin and lack of demonstrable clinical superiority, UFH remains the first-line periprocedural anticoagulant in a pharmacoinvasive strategy. PMID: 31786531 [PubMed - in process]
Source: The Journal of Invasive Cardiology - December 2, 2019 Category: Cardiology Tags: J Invasive Cardiol Source Type: research